asco2002

Cancer Treatment Updates: Highlights from ASCO 2002

NOTE: The broadcast schedule for this program is complete.

If you have questions regarding your educational credit:

Contact the sponsor via e-mail or telephone 609-921-6622.

If you would like to obtain a copy of the certified monograph or the certified videotape:

Please send an e-mail to the publisher.

Financial support for this program is provided by an educational grant from Ortho Biotech Products, L. P.

Moderator:

Robert E. Lynch, MD

Jackson, MS

Faculty:

Corey J. Langer, MD: "Lung Cancer Treatment Updates"

Associate Professor, Department of Medicine

Temple University School of Medicine

Co-Director, Thoracic Oncology

Fox Chase Cancer Center

Philadelphia, PA

Clifford A. Hudis, MD: "Breast Cancer Treatment Updates"

Associate Professor of Clinical Medicine

Joan and Sanford I. Weill Medical College of Cornell University

Memorial Sloan-Kettering Cancer Center

New York, NY

Mohamad Hussein, MD: "Hematological Cancer Treatment Updates"

Director of Multiple Myeloma

The Cleveland Clinic

Cleveland, OH

Peter G. Rose, MD: "Gynecological Cancer Treatment Updates"

Professor, Reproductive Biology and Oncology

Case Western Reserve University School of Medicine

Director, Divisions of Gynecologic Oncology

Metro Health Medical Center

Cleveland, OH

This is a two-hour program which will be rebroadcast:

Live Broadcast:

Wednesday, June 19, 2002, 1 PM Eastern

(12 Noon Central, 11 AM Mountain, 10 AM Pacific)

Rebroadcast:

Tuesday, June 25, 2002, 4 PM Eastern

(3 PM Central, 2 PM Mountain, 1 PM Pacific)

Accreditation:

Physicians: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Seton Hall University School of Graduate Medical Education, the American Academy of CME, Inc. and VitalSigns Healthcare TV. Seton Hall University School of Graduate Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Seton Hall University School of Graduate Medical Education designates this CME activity for a maximum of 2 hours in Category 1 credit toward the American Medical Association Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Pharmacists: Independent Pharmacy Alliance, Inc. is approved by the American Council on Pharmaceutical Education as a provider of continuing pharmaceutical education. Completion of this program provides for 2 hour (0.2 CEU) of continuing education credit. Participants must complete and submit a registration form and the program evaluation form in order to receive CE. Statements of credit will be mailed within 4-6 weeks of the program. The program number for this symposium is 191-999-02-001-L01. There is no cost to attend this symposium.

Nurses: Application has been made for 2 contact hours to the Oncology Nursing Society's Approval Unit. The Oncology Nursing Society is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditation.

Disclosure: It is the policy of Seton Hall University to ensure balance, independence, objectivity, and scientific rigor in all sponsored programs. All faculty participating in programs are expected to disclose to the program audiences any relationship with a manufacturer of any product or device discussed in their presentation.

Objectives: Upon completion of this activity the participants should be able to:

-Interpret key data from current clinical trials presented on lung, breast, hematological and gynecological cancers.

-Compare current and future directions of the evolving treatment of lung, breast, hematological and gynecological cancers.

-Describe the importance of drug interactions, pre-medications, and side effects of chemotherapy.

-Describe the quality of life issues in regard to compliance and use of chemo and radiation therapy.

Target Audience: The primary target audience for this program is medical oncologists, physicians, pharmacists, nurses and other clinicians involved in the care of patients with cancer.